The Great News – Lifestyle
Home
Sample Page
Author:
Halia Therapeutics
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
May 12, 2026